2018 Chronic Heart Failure Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Chronic Heart Failure Market
Chronic heart disease is primarily caused by coronary heart disease and refers to weak heart muscles that fail to pump sufficient blood to the body parts. The venticles grow thicker in size, failing to contract sufficiently to pump the blood. An estimated 5 million to 6 million people suffer from chronic heart failure in the US. Aged populaton is more susceptible to the disease with prevalance of 100 in 1000 people aged above 70 worldwide.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Chronic Heart Failure pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Chronic Heart Failure pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Chronic Heart Failure pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Chronic Heart Failure pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Chronic Heart Failure pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Chronic Heart Failure pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 CHRONIC HEART FAILURE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Chronic Heart Failure Pipeline Snapshot
2.3 Chronic Heart Failure Pipeline by Phase
2.4 Chronic Heart Failure Pipeline by Company
2.5 Chronic Heart Failure Pipeline by Mechanism of Action
3 CHRONIC HEART FAILURE- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd.
Amgen Inc.
ARCA biopharma Inc
Armgo Pharma, Inc.
AstraZeneca Plc
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Capricor Therapeutics, Inc.
Celyad SA
Juventas Therapeutics, Inc.
Servier Laboratories Limited
Mast Therapeutics, Inc.
Mesoblast Limited
Novartis International AG
Pfizer Inc.
Pierre Fabre S.A.
Quantum Genomics SA
scPharmaceuticals Inc
Stemedica Cell Technologies, Inc.
Theravance Biopharma, Inc.
Trio Medicines Ltd
Vifor pharma Group
Zensun (Shanghai) Sci & Tech Co., Ltd.
4 CHRONIC HEART FAILURE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN CHRONIC HEART FAILURE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 CHRONIC HEART FAILURE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Chronic Heart Failure Pipeline Snapshot
2.3 Chronic Heart Failure Pipeline by Phase
2.4 Chronic Heart Failure Pipeline by Company
2.5 Chronic Heart Failure Pipeline by Mechanism of Action
3 CHRONIC HEART FAILURE- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd.
Amgen Inc.
ARCA biopharma Inc
Armgo Pharma, Inc.
AstraZeneca Plc
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Capricor Therapeutics, Inc.
Celyad SA
Juventas Therapeutics, Inc.
Servier Laboratories Limited
Mast Therapeutics, Inc.
Mesoblast Limited
Novartis International AG
Pfizer Inc.
Pierre Fabre S.A.
Quantum Genomics SA
scPharmaceuticals Inc
Stemedica Cell Technologies, Inc.
Theravance Biopharma, Inc.
Trio Medicines Ltd
Vifor pharma Group
Zensun (Shanghai) Sci & Tech Co., Ltd.
4 CHRONIC HEART FAILURE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN CHRONIC HEART FAILURE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Chronic Heart Failure Pipeline by Phase, H2- 2018
Figure 2: Chronic Heart Failure Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Chronic Heart Failure Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Chronic Heart Failure Pipeline by Phase, H2- 2018
Figure 2: Chronic Heart Failure Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Chronic Heart Failure Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Chronic Heart Failure Pipeline by Phase, H2- 2018
Chronic Heart Failure Pipeline by Companies, H2- 2018
Chronic Heart Failure Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 2: Amgen Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 3: ARCA biopharma Inc Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 4: Armgo Pharma, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 5: AstraZeneca Plc Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 6: Bayer AG Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 7: Boehringer Ingelheim GmbH Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 8: Bristol-Myers Squibb Co Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 9: Capricor Therapeutics, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 10: Celyad SA Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 11: Juventas Therapeutics, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 12: Servier Laboratories Limited Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 13: Mast Therapeutics, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 14: Mesoblast Limited Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 15: Novartis International AG Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 16: Pfizer Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 17: Pierre Fabre S.A. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 18: Quantum Genomics SA Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 19: scPharmaceuticals Inc Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 20: Stemedica Cell Technologies, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 21: Theravance Biopharma, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 22: Trio Medicines Ltd Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 23: Vifor pharma Group Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 24: Zensun (Shanghai) Sci & Tech Co., Ltd. Chronic Heart Failure Pipeline Drugs, H2- 2018
Chronic Heart Failure Pipeline by Phase, H2- 2018
Chronic Heart Failure Pipeline by Companies, H2- 2018
Chronic Heart Failure Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 2: Amgen Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 3: ARCA biopharma Inc Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 4: Armgo Pharma, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 5: AstraZeneca Plc Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 6: Bayer AG Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 7: Boehringer Ingelheim GmbH Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 8: Bristol-Myers Squibb Co Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 9: Capricor Therapeutics, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 10: Celyad SA Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 11: Juventas Therapeutics, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 12: Servier Laboratories Limited Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 13: Mast Therapeutics, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 14: Mesoblast Limited Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 15: Novartis International AG Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 16: Pfizer Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 17: Pierre Fabre S.A. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 18: Quantum Genomics SA Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 19: scPharmaceuticals Inc Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 20: Stemedica Cell Technologies, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 21: Theravance Biopharma, Inc. Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 22: Trio Medicines Ltd Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 23: Vifor pharma Group Chronic Heart Failure Pipeline Drugs, H2- 2018
Table 24: Zensun (Shanghai) Sci & Tech Co., Ltd. Chronic Heart Failure Pipeline Drugs, H2- 2018
